Table 7 Dose per participant per session, as reported by the treating SLTs and checked by the research SLT
Participant | Session no | Dose reported | Dose checked | |
|---|---|---|---|---|
SS_Tx_01_F_07 | 4 | 253 | 378 | |
SS_Tx_02_M_12 | 1 | 205 | 266 | |
SS_Tx_02_M_12 | 2 | 317 | 321 | |
SS_Tx_03_M_07 | 3 | 391 | 368 | |
SS_Tx_04_M_05 | 5 | 162 | 163 | |
SS_Tx_04_M_05 | 6 | 116 | 119 | |
SS_Tx_05_M_05 | 4 | 170 | 176 | |
SS_Tx_06_F_09 | 2 | 221 | 224 | |
SS_Tx_06_M_09 | 1 | 152 | 160 | |
SS_Tx_07_M_08 | 1 | 124 | 139 | |
SS_Tx_08_M_07 | 2 | 170 | 212 | |
SS_Tx_09_M_15 | 1 | 179 | 253 | |
SS_Tx_10_F_05 | 2 | 209 | 211 | |
SS_Tx_11_M_07 | 4 | 245 | 159 | |
SS_Tx_12_F_05 | 2 | 109 | 116 | |
SS_Tx_13_F_05 | 3 | 245 | 258 | |
SS_Tx_14_F_04 | 4 | 188 | 213 | |
SS_Tx_15_M_06 | 5 | 230 | 279 | |
SS_Tx_16_F_06 | 5 | 265 | 277 | |
SS_Tx_17_F_10 | 4 | 265 | 330 | |
SS_Tx_18_M_11 | 6 | 249 | 235 | |
SS_Tx_19_M_11 | 2 | 243 | 242 | |